Abstract

The existing study has been designed to consider relationship among polymorphism of CTLA-4 +49 A/G (rs231775) in patients through diabetes mellitus type 2 (T2D). The training has stayed directed on adult at the subdivision of College of Medicine, AlQadisiya University throughout the period prolonged as of October, 2023 to April, 2024. Fifty patients with 50 control healthy assigned to 2 equal groups, collection blood samples with EDTA tubes. The study enrolled 50 Type 2 Diabetes patients and 50 healthy subjects, with no important variances in age, gender, or residency. Demographic appearances displayed no important alteration among the two groups. Chronic illnesses, such as diabetes mellitus and systemic hypertension, were found to be highly significant between patients and control subjects. Hypertension rates were higher in patients than in control subjects, while liver disease rates were higher in patients. Heart attacks were upper in sick than in controlling issues, and hyperlipidemia rates were higher in patients. Drug types and treatment periods were not statistically significant among T2D patients and healthy control. Genomic DNA stayed removed from blood testers by means of a gSYAN DNA kit withdrawal kit and checked using a Nano drop spectrophotometer. The polymorphism of CTLA-4 +49 A/G (rs231775) displayed that the AG genotype and the A allele were more frequent in the type 2 diabetes patients compared to controls, indicating they may be risk factors for developing T2D.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.